I-Mab

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, VRTX has a market cap of 113.9B. Regarding current trading prices, IMAB is priced at $2.67, while VRTX trades at $443.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas VRTX's P/E ratio is -115.47. In terms of profitability, IMAB's ROE is -0.04%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, IMAB is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, REGN has a market cap of 55.3B. Regarding current trading prices, IMAB is priced at $2.67, while REGN trades at $525.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas REGN's P/E ratio is 13.24. In terms of profitability, IMAB's ROE is -0.04%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IMAB is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IMAB is priced at $2.67, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IMAB's ROE is -0.04%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IMAB is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ALNY has a market cap of 41.5B. Regarding current trading prices, IMAB is priced at $2.67, while ALNY trades at $317.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ALNY's P/E ratio is -150.83. In terms of profitability, IMAB's ROE is -0.04%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, IMAB is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ARGX has a market cap of 34.2B. Regarding current trading prices, IMAB is priced at $2.67, while ARGX trades at $558.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ARGX's P/E ratio is 34.17. In terms of profitability, IMAB's ROE is -0.04%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, IMAB is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, BNTX has a market cap of 25.5B. Regarding current trading prices, IMAB is priced at $2.67, while BNTX trades at $105.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas BNTX's P/E ratio is -29.00. In terms of profitability, IMAB's ROE is -0.04%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, IMAB is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IMAB is priced at $2.67, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IMAB's ROE is -0.04%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, IMAB is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RPRX has a market cap of 19.8B. Regarding current trading prices, IMAB is priced at $2.67, while RPRX trades at $35.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RPRX's P/E ratio is 14.40. In terms of profitability, IMAB's ROE is -0.04%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, IMAB is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IMAB is priced at $2.67, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IMAB's ROE is -0.04%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, IMAB is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, SMMT has a market cap of 15.8B. Regarding current trading prices, IMAB is priced at $2.67, while SMMT trades at $21.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas SMMT's P/E ratio is -62.71. In terms of profitability, IMAB's ROE is -0.04%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, IMAB is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, INCY has a market cap of 13.7B. Regarding current trading prices, IMAB is priced at $2.67, while INCY trades at $70.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas INCY's P/E ratio is 354.05. In terms of profitability, IMAB's ROE is -0.04%, compared to INCY's ROE of +0.01%. Regarding short-term risk, IMAB is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, GMAB has a market cap of 12.8B. Regarding current trading prices, IMAB is priced at $2.67, while GMAB trades at $20.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas GMAB's P/E ratio is 12.19. In terms of profitability, IMAB's ROE is -0.04%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, IMAB is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, UTHR has a market cap of 12.8B. Regarding current trading prices, IMAB is priced at $2.67, while UTHR trades at $285.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas UTHR's P/E ratio is 11.32. In terms of profitability, IMAB's ROE is -0.04%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IMAB is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IMAB is priced at $2.67, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IMAB's ROE is -0.04%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IMAB is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, IMAB is priced at $2.67, while EXEL trades at $43.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas EXEL's P/E ratio is 19.68. In terms of profitability, IMAB's ROE is -0.04%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, IMAB is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MRNA has a market cap of 10.6B. Regarding current trading prices, IMAB is priced at $2.67, while MRNA trades at $27.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MRNA's P/E ratio is -3.15. In terms of profitability, IMAB's ROE is -0.04%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, IMAB is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ASND has a market cap of 10.4B. Regarding current trading prices, IMAB is priced at $2.67, while ASND trades at $171.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ASND's P/E ratio is -25.97. In terms of profitability, IMAB's ROE is -0.04%, compared to ASND's ROE of +1.91%. Regarding short-term risk, IMAB is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, IMAB is priced at $2.67, while BMRN trades at $54.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas BMRN's P/E ratio is 20.04. In terms of profitability, IMAB's ROE is -0.04%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, IMAB is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IMAB is priced at $2.67, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IMAB's ROE is -0.04%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IMAB is priced at $2.67, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IMAB's ROE is -0.04%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, IMAB is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, BBIO has a market cap of 8.6B. Regarding current trading prices, IMAB is priced at $2.67, while BBIO trades at $45.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas BBIO's P/E ratio is -12.67. In terms of profitability, IMAB's ROE is -0.04%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, IMAB is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, IMAB is priced at $2.67, while BPMC trades at $128.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas BPMC's P/E ratio is -51.26. In terms of profitability, IMAB's ROE is -0.04%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, IMAB is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, IMAB is priced at $2.67, while TECH trades at $52.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas TECH's P/E ratio is 63.61. In terms of profitability, IMAB's ROE is -0.04%, compared to TECH's ROE of +0.06%. Regarding short-term risk, IMAB is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IMAB is priced at $2.67, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CERE's P/E ratio is -16.47. In terms of profitability, IMAB's ROE is -0.04%, compared to CERE's ROE of -0.43%. Regarding short-term risk, IMAB is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, VRNA has a market cap of 8B. Regarding current trading prices, IMAB is priced at $2.67, while VRNA trades at $93.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas VRNA's P/E ratio is -47.20. In terms of profitability, IMAB's ROE is -0.04%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, IMAB is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, IMAB is priced at $2.67, while ROIV trades at $11.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ROIV's P/E ratio is -15.47. In terms of profitability, IMAB's ROE is -0.04%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, IMAB is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CORT has a market cap of 7.9B. Regarding current trading prices, IMAB is priced at $2.67, while CORT trades at $74.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CORT's P/E ratio is 64.63. In terms of profitability, IMAB's ROE is -0.04%, compared to CORT's ROE of +0.20%. Regarding short-term risk, IMAB is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, IMAB is priced at $2.67, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, IMAB's ROE is -0.04%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, IMAB is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RVMD has a market cap of 7B. Regarding current trading prices, IMAB is priced at $2.67, while RVMD trades at $37.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RVMD's P/E ratio is -9.35. In terms of profitability, IMAB's ROE is -0.04%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, IMAB is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MDGL has a market cap of 6.7B. Regarding current trading prices, IMAB is priced at $2.67, while MDGL trades at $299.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MDGL's P/E ratio is -16.80. In terms of profitability, IMAB's ROE is -0.04%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, IMAB is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, AMRN has a market cap of 6.6B. Regarding current trading prices, IMAB is priced at $2.67, while AMRN trades at $15.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas AMRN's P/E ratio is -3.61. In terms of profitability, IMAB's ROE is -0.04%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, IMAB is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IMAB is priced at $2.67, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RETA's P/E ratio is -66.29. In terms of profitability, IMAB's ROE is -0.04%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IMAB is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, JAZZ has a market cap of 6.5B. Regarding current trading prices, IMAB is priced at $2.67, while JAZZ trades at $108.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas JAZZ's P/E ratio is 14.61. In terms of profitability, IMAB's ROE is -0.04%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, IMAB is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, HALO has a market cap of 6.5B. Regarding current trading prices, IMAB is priced at $2.67, while HALO trades at $52.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas HALO's P/E ratio is 13.97. In terms of profitability, IMAB's ROE is -0.04%, compared to HALO's ROE of +1.22%. Regarding short-term risk, IMAB is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, IONS has a market cap of 6.3B. Regarding current trading prices, IMAB is priced at $2.67, while IONS trades at $39.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas IONS's P/E ratio is -13.30. In terms of profitability, IMAB's ROE is -0.04%, compared to IONS's ROE of -0.92%. Regarding short-term risk, IMAB is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, TGTX has a market cap of 6B. Regarding current trading prices, IMAB is priced at $2.67, while TGTX trades at $37.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas TGTX's P/E ratio is 151.80. In terms of profitability, IMAB's ROE is -0.04%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, IMAB is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, TLX has a market cap of 5.5B. Regarding current trading prices, IMAB is priced at $2.67, while TLX trades at $15.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas TLX's P/E ratio is 182.22. In terms of profitability, IMAB's ROE is -0.04%, compared to TLX's ROE of +0.14%. Regarding short-term risk, IMAB is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IMAB is priced at $2.67, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IMAB's ROE is -0.04%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IMAB is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IMAB is priced at $2.67, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IMAB's ROE is -0.04%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IMAB is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, IMAB is priced at $2.67, while NUVL trades at $79.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas NUVL's P/E ratio is -17.90. In terms of profitability, IMAB's ROE is -0.04%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, IMAB is priced at $2.67, while AXSM trades at $103.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas AXSM's P/E ratio is -17.78. In terms of profitability, IMAB's ROE is -0.04%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, IMAB is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, IMAB is priced at $2.67, while ALKS trades at $28.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ALKS's P/E ratio is 13.73. In terms of profitability, IMAB's ROE is -0.04%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, IMAB is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IMAB is priced at $2.67, while AKRO trades at $56.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas AKRO's P/E ratio is -15.02. In terms of profitability, IMAB's ROE is -0.04%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, IMAB is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IMAB is priced at $2.67, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IMAB's ROE is -0.04%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, IMAB is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, IMAB is priced at $2.67, while ADMA trades at $18.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ADMA's P/E ratio is 21.89. In terms of profitability, IMAB's ROE is -0.04%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, IMAB is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $2.67, while PCVX trades at $32.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas PCVX's P/E ratio is -8.24. In terms of profitability, IMAB's ROE is -0.04%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, IMAB is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, SLNO has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $2.67, while SLNO trades at $83.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas SLNO's P/E ratio is -17.73. In terms of profitability, IMAB's ROE is -0.04%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, IMAB is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $2.67, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas OPT's P/E ratio is -1.52. In terms of profitability, IMAB's ROE is -0.04%, compared to OPT's ROE of +2.60%. Regarding short-term risk, IMAB is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, KRYS has a market cap of 4.1B. Regarding current trading prices, IMAB is priced at $2.67, while KRYS trades at $141.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas KRYS's P/E ratio is 34.19. In terms of profitability, IMAB's ROE is -0.04%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, IMAB is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IMAB is priced at $2.67, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IMAB's ROE is -0.04%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IMAB is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CYTK has a market cap of 4B. Regarding current trading prices, IMAB is priced at $2.67, while CYTK trades at $34.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CYTK's P/E ratio is -6.41. In terms of profitability, IMAB's ROE is -0.04%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, IMAB is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CRSP has a market cap of 4B. Regarding current trading prices, IMAB is priced at $2.67, while CRSP trades at $46.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CRSP's P/E ratio is -10.41. In terms of profitability, IMAB's ROE is -0.04%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, IMAB is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ZLAB has a market cap of 4B. Regarding current trading prices, IMAB is priced at $2.67, while ZLAB trades at $34.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ZLAB's P/E ratio is -14.48. In terms of profitability, IMAB's ROE is -0.04%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, IMAB is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MRUS has a market cap of 4B. Regarding current trading prices, IMAB is priced at $2.67, while MRUS trades at $52.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MRUS's P/E ratio is -12.78. In terms of profitability, IMAB's ROE is -0.04%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, IMAB is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, IMAB is priced at $2.67, while PTCT trades at $49.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas PTCT's P/E ratio is 7.61. In terms of profitability, IMAB's ROE is -0.04%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, IMAB is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RYTM has a market cap of 3.9B. Regarding current trading prices, IMAB is priced at $2.67, while RYTM trades at $61.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RYTM's P/E ratio is -21.94. In terms of profitability, IMAB's ROE is -0.04%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, IMAB is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IMAB is priced at $2.67, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IMAB's ROE is -0.04%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IMAB is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IMAB is priced at $2.67, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IMAB's ROE is -0.04%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IMAB is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, IMAB is priced at $2.67, while ACAD trades at $22.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ACAD's P/E ratio is 16.20. In terms of profitability, IMAB's ROE is -0.04%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, IMAB is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RNA has a market cap of 3.6B. Regarding current trading prices, IMAB is priced at $2.67, while RNA trades at $30.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RNA's P/E ratio is -9.94. In terms of profitability, IMAB's ROE is -0.04%, compared to RNA's ROE of -0.27%. Regarding short-term risk, IMAB is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ACLX has a market cap of 3.6B. Regarding current trading prices, IMAB is priced at $2.67, while ACLX trades at $63.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ACLX's P/E ratio is -21.66. In terms of profitability, IMAB's ROE is -0.04%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, IMAB is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $2.67, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IMAB's ROE is -0.04%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, IMAB is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $2.67, while AAPG trades at $39.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas AAPG's P/E ratio is -54.41. In terms of profitability, IMAB's ROE is -0.04%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, IMAB is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $2.67, while RARE trades at $37.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RARE's P/E ratio is -6.37. In terms of profitability, IMAB's ROE is -0.04%, compared to RARE's ROE of -1.86%. Regarding short-term risk, IMAB is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, IMAB is priced at $2.67, while PTGX trades at $55.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas PTGX's P/E ratio is 70.79. In terms of profitability, IMAB's ROE is -0.04%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, IMAB is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, SRRK has a market cap of 3.4B. Regarding current trading prices, IMAB is priced at $2.67, while SRRK trades at $35.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas SRRK's P/E ratio is -13.91. In terms of profitability, IMAB's ROE is -0.04%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, IMAB is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, VKTX has a market cap of 3.2B. Regarding current trading prices, IMAB is priced at $2.67, while VKTX trades at $27.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas VKTX's P/E ratio is -24.28. In terms of profitability, IMAB's ROE is -0.04%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, IMAB is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, LEGN has a market cap of 3.1B. Regarding current trading prices, IMAB is priced at $2.67, while LEGN trades at $34.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas LEGN's P/E ratio is -28.37. In terms of profitability, IMAB's ROE is -0.04%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, IMAB is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MTSR has a market cap of 3B. Regarding current trading prices, IMAB is priced at $2.67, while MTSR trades at $28.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MTSR's P/E ratio is -11.30. In terms of profitability, IMAB's ROE is -0.04%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, IMAB is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MLTX has a market cap of 3B. Regarding current trading prices, IMAB is priced at $2.67, while MLTX trades at $47.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MLTX's P/E ratio is -20.57. In terms of profitability, IMAB's ROE is -0.04%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, IMAB is priced at $2.67, while KYMR trades at $45.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas KYMR's P/E ratio is -14.70. In terms of profitability, IMAB's ROE is -0.04%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, IMAB is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, IMAB is priced at $2.67, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MORF's P/E ratio is -14.88. In terms of profitability, IMAB's ROE is -0.04%, compared to MORF's ROE of -0.22%. Regarding short-term risk, IMAB is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, IMAB is priced at $2.67, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MOR's P/E ratio is -12.64. In terms of profitability, IMAB's ROE is -0.04%, compared to MOR's ROE of +2.51%. Regarding short-term risk, IMAB is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, IMAB is priced at $2.67, while CRNX trades at $30.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CRNX's P/E ratio is -7.89. In terms of profitability, IMAB's ROE is -0.04%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, IMAB is priced at $2.67, while IMVT trades at $16.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas IMVT's P/E ratio is -6.00. In terms of profitability, IMAB's ROE is -0.04%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, IMAB is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, IMAB is priced at $2.67, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas KDNY's P/E ratio is -12.47. In terms of profitability, IMAB's ROE is -0.04%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, IMAB is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, IMAB is priced at $2.67, while CPRX trades at $21.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CPRX's P/E ratio is 13.94. In terms of profitability, IMAB's ROE is -0.04%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, IMAB is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, IMAB is priced at $2.67, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MYOV's P/E ratio is -14.05. In terms of profitability, IMAB's ROE is -0.04%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, IMAB is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, APGE has a market cap of 2.6B. Regarding current trading prices, IMAB is priced at $2.67, while APGE trades at $44.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas APGE's P/E ratio is -12.13. In terms of profitability, IMAB's ROE is -0.04%, compared to APGE's ROE of -0.19%. Regarding short-term risk, IMAB is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, IMAB is priced at $2.67, while MIRM trades at $50.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas MIRM's P/E ratio is -31.40. In terms of profitability, IMAB's ROE is -0.04%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, IMAB is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, IMAB is priced at $2.67, while XENE trades at $32.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas XENE's P/E ratio is -10.00. In terms of profitability, IMAB's ROE is -0.04%, compared to XENE's ROE of -0.32%. Regarding short-term risk, IMAB is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, IBRX has a market cap of 2.5B. Regarding current trading prices, IMAB is priced at $2.67, while IBRX trades at $2.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas IBRX's P/E ratio is -4.89. In terms of profitability, IMAB's ROE is -0.04%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, IMAB is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, IMAB is priced at $2.67, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas PRVB's P/E ratio is -16.43. In terms of profitability, IMAB's ROE is -0.04%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, IMAB is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, IMAB is priced at $2.67, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas LBPH's P/E ratio is -26.66. In terms of profitability, IMAB's ROE is -0.04%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, IMAB is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, APLS has a market cap of 2.3B. Regarding current trading prices, IMAB is priced at $2.67, while APLS trades at $18.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas APLS's P/E ratio is -10.22. In terms of profitability, IMAB's ROE is -0.04%, compared to APLS's ROE of -1.00%. Regarding short-term risk, IMAB is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, IMAB is priced at $2.67, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas DICE's P/E ratio is -21.91. In terms of profitability, IMAB's ROE is -0.04%, compared to DICE's ROE of +0.56%. Regarding short-term risk, IMAB is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, IMAB is priced at $2.67, while LGND trades at $114.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas LGND's P/E ratio is -15.87. In terms of profitability, IMAB's ROE is -0.04%, compared to LGND's ROE of -0.16%. Regarding short-term risk, IMAB is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, IMAB is priced at $2.67, while ARWR trades at $16.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas ARWR's P/E ratio is -12.96. In terms of profitability, IMAB's ROE is -0.04%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, IMAB is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, RXRX has a market cap of 2.2B. Regarding current trading prices, IMAB is priced at $2.67, while RXRX trades at $5.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas RXRX's P/E ratio is -3.00. In terms of profitability, IMAB's ROE is -0.04%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, IMAB is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, IMAB is priced at $2.67, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CALT's P/E ratio is -22.73. In terms of profitability, IMAB's ROE is -0.04%, compared to CALT's ROE of -1.67%. Regarding short-term risk, IMAB is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, IMAB is priced at $2.67, while DNLI trades at $14.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas DNLI's P/E ratio is -5.43. In terms of profitability, IMAB's ROE is -0.04%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, IMAB is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, IMAB is priced at $2.67, while VCYT trades at $26.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas VCYT's P/E ratio is 63.83. In terms of profitability, IMAB's ROE is -0.04%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, IMAB is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, IMAB is priced at $2.67, while VCEL trades at $41.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas VCEL's P/E ratio is 833.20. In terms of profitability, IMAB's ROE is -0.04%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, IMAB is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, IMAB is priced at $2.67, while KNSA trades at $28.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas KNSA's P/E ratio is -118.67. In terms of profitability, IMAB's ROE is -0.04%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, IMAB is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, NAMS has a market cap of 2.1B. Regarding current trading prices, IMAB is priced at $2.67, while NAMS trades at $18.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas NAMS's P/E ratio is -10.03. In terms of profitability, IMAB's ROE is -0.04%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, IMAB is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, BCRX has a market cap of 2B. Regarding current trading prices, IMAB is priced at $2.67, while BCRX trades at $9.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas BCRX's P/E ratio is -37.12. In terms of profitability, IMAB's ROE is -0.04%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, IMAB is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, CGON has a market cap of 2B. Regarding current trading prices, IMAB is priced at $2.67, while CGON trades at $26.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas CGON's P/E ratio is -17.38. In terms of profitability, IMAB's ROE is -0.04%, compared to CGON's ROE of -0.17%. Regarding short-term risk, IMAB is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, IDYA has a market cap of 2B. Regarding current trading prices, IMAB is priced at $2.67, while IDYA trades at $22.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas IDYA's P/E ratio is -6.11. In terms of profitability, IMAB's ROE is -0.04%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, IMAB is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.

IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMAB stands at 165M. In comparison, BLTE has a market cap of 1.9B. Regarding current trading prices, IMAB is priced at $2.67, while BLTE trades at $59.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMAB currently has a P/E ratio of -3.74, whereas BLTE's P/E ratio is -44.04. In terms of profitability, IMAB's ROE is -0.04%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, IMAB is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.